National Institute of Allergy and Infectious Diseases (NIAID): Severe Acute Respiratory Syndrome trials

The registry lists 10 Severe Acute Respiratory Syndrome studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 2 2Phase 3 3Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Steroid Treatment for Severe Acute Respiratory Infection (STAR) TrialNot yet recruitingNCT07199192Phase 4
• Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729606Phase 3Results posted
• Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729593Phase 3Results posted
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 3Results posted
• COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
• COVID-19 and Anti-CD14 Treatment TrialTerminatedNCT04391309Phase 2Results posted
• COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-CCompletedNCT04588363
• Collection of Convalescent SARS Plasma by ApheresisCompletedNCT00342524
• Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)WithdrawnNCT00073086
• Investigating Severe Acute Respiratory Syndrome (SARS)CompletedNCT00066209